Voyager raised 2026 revenue guidance to $225M–$255M (35%–53% YoY) and reported a record backlog of $266M (+33% YoY) with a $1.6B pipeline tied to Golden Dome, improving top-line visibility. Near-term profitability is challenged: adjusted EBITDA widened to a $69.9M loss and the company is guiding to another EBITDA loss in 2026, while targeting positive adjusted EBITDA in 2027 and free cash flow positivity in 2028; gross margin expected in the mid‑teens for 2026. StarLab has hit 31 milestones with $183M in NASA receipts, 100% commercial payload capacity reserved, Voyager retaining just above 60% ownership, and StarLab expected to be roughly cash‑neutral in 2026. Liquidity exceeds $700M (cash $491M + $213M credit facilities) and 2026 CapEx ex‑StarLab is forecast at $60M–$70M to scale the Voyager American Defense Complex and vertical integration (Voyager Energetics).
Voyager’s strategy to vertically integrate energetics and onshore propulsion creates a wedge between primes and legacy suppliers: by owning upstream energetic manufacturing and a dedicated ADC, Voyager can compress supplier lead-times and capture value that normally accrues to large primes during scale-up. The second‑order effect is bargaining leverage on milestone timing — primes facing urgent replenishment needs will be willing to accelerate milestone-funded payments or prepayments to trusted, on‑shore suppliers, turning working capital into a competitive moat for firms that can deliver capacity fast. The next 9–18 months are binary and event-driven: CLD Phase‑2 outcome and the flow of government milestone/advance payments are the primary liquidity and valuation inflection points. Execution risks that would reverse the thesis are conventional (manufacturing delays, feedstock shortages) and idiosyncratic (StarLab JV underfunding or a CLD delay). Policy and budget tailwinds (defense onshoring, accelerated procurement) shorten typical defense procurement timelines here, but they also raise CapEx needs and R&D burn in the near term — meaning upside is concentrated if backlog converts on schedule, downside if awards slip or technical gates are missed. From a competitive-market perspective, expect mid‑tier subcontractors and specialized chem suppliers to be the immediate losers: domestic onshoring will reallocate addressable spend away from offshore vendors and small integrators that lack scale or capital to invest in surge capacity. For portfolio construction this argues for a barbell approach — small, option‑like exposure to Voyager to capture high upside if Golden Dome/CLD outcomes materialize, plus larger, lower‑volatility exposure to high‑quality primes that will capture follow‑on production spend and takeouts as program risk declines.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment